TrialPath
Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336 · AbbVie
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer
About this study
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world. In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Eligibility criteria
Inclusion Criteria: * Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization \[WHO\] criteria). * Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion. For Parts 1-4: \- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy). For Parts 5-6: \- Participants will have platinum-sensitive disease defined as radiographic progression \> 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression. Exclusion Criteria: * Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor. * Participants with platinum refractory disease. * Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor. * Prior history of Grade \>= 2 interstitial lung disease (ILD) or pneumonitis. * Prior history of Grade 2 \>= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan. For Parts 3-6: * History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab. * History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted). * Echocardiogram with ejection fraction \<= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity. For Parts 5-6: \- Participants who had prior allergic reaction to platinum containing compound.
Study design
Enrollment target: 285 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-11-27
Estimated completion: 2029-01
Last updated: 2026-10-13
Interventions
Drug: ABBV-901Drug: BevacizumabDrug: Carboplatin
Primary outcomes
  • • Number of Participants with Adverse Events (AE) (Up to Approximately 3 Years)
  • • Overall Response (as assessed by the investigator) (Up to Approximately 3 Years)
Sponsor
AbbVie · industry
Contacts & investigators
ContactABBVIE CALL CENTER · contact · abbvieclinicaltrials@abbvie.com · 844-663-3742
InvestigatorABBVIE INC. · study_director, AbbVie
All locations (27)
City of Hope National Medical Center /ID# 281381Recruiting
Duarte, California, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914Recruiting
Irvine, California, United States
Sarah Cannon Research Institute at HealthONE /ID# 278785Recruiting
Denver, Colorado, United States
University of Chicago Medical Center /ID# 278295Recruiting
Chicago, Illinois, United States
University Of Nebraska Medical Center /ID# 281020Recruiting
Omaha, Nebraska, United States
NEXT Oncology - San Antonio /ID# 278606Recruiting
San Antonio, Texas, United States
Start Mountain Region /ID# 278609Recruiting
West Valley City, Utah, United States
Next Virginia /ID# 278607Recruiting
Fairfax, Virginia, United States
Blacktown Hospital /ID# 282426Recruiting
Blacktown, New South Wales, Australia
Monash Health - Monash Medical Centre - Clayton /ID# 281468Recruiting
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre. /ID# 281751Recruiting
Melbourne, Victoria, Australia
Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684Recruiting
Saint-Herblain, Pays de la Loire Region, France
Centre Leon Berard /ID# 280575Recruiting
Lyon, Rhone, France
The Chaim Sheba Medical Center /ID# 278416Recruiting
Ramat Gan, Tel Aviv, Israel
Rambam Health Care Campus /ID# 278418Recruiting
Haifa, Israel
Hadassah Medical Center-Hebrew University /ID# 278420Recruiting
Jerusalem, Israel
National Cancer Center Hospital East /ID# 278604Recruiting
Kashiwa-shi, Chiba, Japan
Saitama Medical University International Medical Center /ID# 278437Recruiting
Hidaka, Saitama, Japan
Shizuoka Cancer Center /ID# 278538Recruiting
Sunto-gun, Shizuoka, Japan
Unidade Local de Saude de Santa Maria /ID# 280296Recruiting
Lisbon, Portugal
Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293Recruiting
Porto, Portugal
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459Recruiting
Majadahonda, Madrid, Spain
Hospital Universitari Vall d Hebron /ID# 280442Recruiting
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz /ID# 280440Recruiting
Madrid, Spain
Hospital Universitario HM Sanchinarro /ID# 280439Recruiting
Madrid, Spain
National Taiwan University Hospital /ID# 280701Recruiting
Taipei, Taiwan
Taipei Veterans General Hospital /ID# 281349Recruiting
Taipei, Taiwan
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer · TrialPath